Liraglutide
Abdominal Obesity-Metabolic Syndrome
Explore 42 assets in Abdominal Obesity-Metabolic Syndrome →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
University of Virginia
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04575844CT.gov Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome | — | Recruiting | — | — | — |
NCT03642600CT.gov The Gut Microbiome in Women With Polycystic Ovary Syndrome | — | Completed | — | — | — |
NCT02743598CT.gov Liraglutide for HIV-associated Neurocognitive Disorder | — | Terminated | — | — | — |
NCT02660047CT.gov Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent | — | Completed | — | — | — |
NCT01761318CT.gov Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients | — | Completed | — | — | — |
NCT01234649CT.gov Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Abdominal Obesity-Metabolic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Liraglutide (this asset) | University of Virginia | Approved | BB · 68 |
| Atorvastatin | Seoul National University Hospital | P4 | BBB |
| Topiramate | All India Institute of Medical Sciences, Bhubaneswar | P4 | BBB |
| Pioglitazone | Philip Kern | P4 | BBB |
| Rosuvastatin | Hamdard University | P4 | BBB |
| Simvastatin | Jaime Daniel Mondragon | P4 | BBB |
| Olmesartan Medoxomil | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | P4 | BBB |
| Amlodipine | Italo Biaggioni | P4 | BB |
| Ezetimibe | Samsung Medical Center | P4 | BB |
+42 more in the Abdominal Obesity-Metabolic Syndrome cohort
Other indications for Liraglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 84 |
| Type 1 Diabetes Mellitus | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Liraglutide in Abdominal Obesity-Metabolic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/liraglutide-abdominal-obesity-metabolic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →